Global Fund Discontinues Funding for South Africa's loveLife Program; loveLife Responds
December 22, 2005
The Global Fund To Fight AIDS, Tuberculosis and Malaria has decided not to continue funding loveLife, South Africa's national HIV prevention program for youth, the Mail & Guardian reports (Chibba, Mail & Guardian, 12/21). The Global Fund -- which over the past two years accounted for about 30% of loveLife's budget -- was considering a further three-year, $43 million grant for the program (loveLife release, 12/21). loveLife -- which began in 1999 and is organized under the auspices of the independent loveLife Trust governed by leading South Africans -- aims to reduce the number of HIV infections among young South Africans through youth-friendly HIV/AIDS services in government clinics, outreach programs in schools and through a national network of community-based organizations, combined with a high-profile HIV education and awareness campaign. The program's other major funders include the South African government and the Kaiser Family Foundation. loveLife also receives major South African corporate sector support (Kaiser Daily HIV/AIDS Report, 9/26). In London's Times, former South African President Nelson Mandela in September wrote, "[I]n South Africa, where our young people have one of the highest rates of HIV infection in the world, there are promising signs that the largest of our HIV prevention efforts -- loveLife -- is paying off," adding, "More than 85% of South Africa's youth report that they are aware of loveLife, and one-third have participated in at least one loveLife program. Most hopeful, though, according to a new, large-scale study published in [September], young people who participated in loveLife programs were 'significantly less likely to be HIV infected'" (Kaiser Daily HIV/AIDS Report, 9/27).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2005 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Aurobindo Pharma Receives Tentative FDA Approval to Produce Pediatric Version of Generic Antiretroviral Stavudine for PEPFAR
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.